Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Wilhem Leconet1, He Liu1, Ming Guo1, Sophie Le Lamer-D’echamps2, Charlotte Molinier1, Sae Kim1, Tjasa Vrlinic2, Murielle Oster2, Fang Liu2, Vicente Navarro1, Jaspreet S. Batra1, Adolfo Lopez Noriega2, Sylvestre Grizot2, and Neil H. Bander1

Abstract

Small therapeutic proteins represent a promising novel approach to treat cancer. Nevertheless, their clinical application is often adversely impacted by their short plasma half-life. Controlled long-term delivery of small biologicals has become a challenge because of their hydrophilic properties and in some cases their limited stability. Here, an in situ forming depot-injectable polymeric system was used to deliver BiJ591, a bispecific T-cell engager (BiTE) targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer. BiJ591 induced T-cell activation, prostate cancer-directed cell lysis, and tumor growth inhibition. The use of diblock (DB) and triblock (TB) biodegradable polyethylene glycol−poly(lactic acid; PEG−PLA) copolymers solubilized in tripropionin, a small-chain triglyceride, allowed maintenance of BiJ591 stability and functionality in the formed depot and controlled its release. In mice, after a single subcutaneous injection, one of the polymeric candidates, TB1/DB4, provided the most sustained release of BiJ591 for up to 21 days. Moreover, the use of BiJ591-TB1/DB4 formulation in prostate cancer xenograft models showed significant therapeutic activity in both low and high PSMA--expressing tumors, whereas daily intravenous administration of BiJ591 was less efficient. Collectively, these data provide new insights into the development of controlled delivery of small therapeutic proteins in cancer.

Introduction

Antibodies are today among the most attractive cancer therapeutics agents due to their target specificity, but also for their ability to be engineered, improving their cytotoxic properties against the targeted cancer cells (1, 2). Among these antibody-based drugs, bispecific antibodies can engage two targets simultaneously, the second antigen can be either tumor specific or from another cell type (3). There are two bispecific antibodies that have been approved in the clinic, blinatumomab and catumaxomab (discontinued in 2014 for commercial reasons), which the ability to target a cancer cell marker (CD19 and EpCAM, respectively) and CD3, a T-cell coreceptor well known to activate T cell and targeted cell. Their relatively small molecular weight of 55 kDa could also provide improved tumor penetration (7), but is associated with a short plasma half-life of approximately 2 hours. Therefore, patients with acute lymphoblastic leukemia (ALL) require an infusion pump to deliver a constant flow rate of blinatumomab (8). Nevertheless, the use of this device is not optimal for patient comfort and contributes to the high cost of the treatment. The replacement of this device by a low-cost long acting biodegradable technology could provide a substantial benefit for patient comfort as well as reduce healthcare costs, and make the treatment approach more available in areas of the world that are resource constrained.

The quest for an appropriate controlled release system for protein therapeutics is challenging, given the intrinsic fragility of the macromolecule as well as the costs of the drug product manufacturing and possibly the device. Over the last decades, intense investigations have been performed using biodegradable and biocompatible polymers as solid implants, particles, or injectable depots to entrap proteins and release them through the degradation of the polymer depot (9–12). The use of a polymeric controlled release system for BiTE-like proteins is an interesting novel approach, but has to fulfill
dose of a BiJ591 polymeric formulation injected subcutaneously or intravenous administration. Body in cancer xenograft models in comparison with a daily positive prostate cancer models—biodegradable polyethylene glycol (PEG) was formulated in a long-acting injectable technology drug—demonstrating the specificity of the antigen (PSMA) J591 antibody (20) was used to design a BiTE formulation such as its viscosity and the degradation and release kinetics from the depot upon administration (18, 19). In this study, the scfV of the anti-prostate specific membrane antigen (PSMA) J591 antibody (20) was used to design a BiTE antibody, designated BiJ591, targeting PSMA and CD3. After demonstrating the specific cytotoxicity of BiJ591 to PSMA-positive prostate cancer models in vitro and in vivo, the protein was formulated in a long-acting injectable technology drug—delivery system composed of diblock (DB) and triblock (TB) biodegradable polyethylene glycol (PEG)—poly(lactic acid; PLA) copolymers solubilized in tripropionin, a small-chain triglyceride. The stability and functionality of BiJ591 throughout the formulation process were demonstrated, and a single dose of a BiJ591 polymeric formulation injected subcutaneously significantly improved the apparent elimination half-life as well as the in vivo antitumor activity of the bispecific antibody in cancer xenograft models in comparison with a daily intravenous administration.

Material and Methods
Expression, production, and purification of BiJ591
BiJ591 cDNA sequence was synthesized in silico, using the GeneArt Gene Synthesis software (Invitrogen), by fusing the VH/VI regions of deimmunized anti-PSMA antibody J591 to the VH/VI region of anti-CD3 antibody OKT-3, using a (G4S) linker. 6xHis and c-Myc tags were added at the C-terminal region of the cDNA sequence to purify and detect the recombinant protein (Fig. 1A). Chinese Hamster Ovary (CHO) cells were transfected with the pcDNA3.1-BiJ591 plasmid using FreeStyle MAX Reagent according to the manufacturer's protocol (Invitrogen). BiJ591 was purified from CHO supernatant using a Cobalt HiTrap TALON column (GE Healthcare), a yield of 10 mg of BiJ591 per liter of supernatant was obtained. Analysis of BiJ591 purity was performed by SDS-PAGE and Coomassie Blue staining.

Cell lines and culture
The LNCaP, PC-3 Wild-Type (PC-3 WT), MDA PCa 2b prostate cancer cell lines were obtained from ATCC. CWR22Rv1 and PC-3-PSMA were gifts, respectively, from Thomas Pretlow, MD (Case Western Reserve University, Cleveland, OH) and Michel Sadelain, PhD (Memorial Sloan Kettering Cancer Center, New York, NY). PC-3 WT, CWR22Rv1, LNCaP cells were routinely maintained in RPMI1640 (Mediatech, Inc.) supplemented with 10% FBS, 1% penicillin–streptomycin, and 2 mmol/L L-glutamine (all reagents from Gemini Bio-products). MDA PCa 2b cells were grown in DMEM/F12 medium (ATCC) containing 20% FBS, 1% penicillin–streptomycin, 2 mmol/L L-glutamine, 10 ng/mL EGF (BD Biosciences), 25 ng/mL cholora toxin, 5 μmol/L phosphoethanolamine, 100 pg/mL hydrocortisone, 45 mmol/L selenious acid, and 5 μg/mL insulin (all from Sigma-Aldrich). All cell lines were tested for Mycoplasma contamination and authenticated by DNA Diagnostics Center prior to experiments.

BiJ591-dependent cell cytotoxicity and cytokine release
J591 constructs (huJ591, scFvJ591, and BiJ591) were incubated at various concentrations with either PBMCs or purified CD3 T cells for 30 minutes. Then, target prostate cancer cells were added at different E:T ratios for 5 hours. Cytotoxicity was measured by lactate dehydrogenase (LDH) release assay using Cytotoxicity Detection Kit from Roche and following the kit’s instructions. Human peripheral blood mononuclear cells (huPBMC) were isolated by Ficoll density gradient centrifugation, and enrichment for CD3 T cells was conducted by using RosetteSep Human T-cell Enrichment Cocktail (StemCell Technologies). Cytokines (IL2, IL4, IL6, IL10, IFNγ, and TNFα) release concentration was determined in supernatants of cytotoxicity assays using a commercially available FACS-based cytokmetric bead array (CBA-Kit, BD Biosciences) in accordance with the manufacturer’s protocol.

PSMA- and CD3-binding studies
The ability of purified BiJ591 to bind with both PSMA and CD3 before and after the spray-drying process described below was measured by flow cytometry, using full antibodies J591 and OKT-3 as positive controls and 6xHis-Tag mouse mAb and anti-mouse IgG-alexa fluor 488 as secondary antibodies (Thermo Fisher Scientific). To assess BiJ591 functionality during the in vitro release (IVR) experiment described below, Jurkat and LNCaP cells were incubated with each IVR sample and the BiJ591 amount was determined by comparing the fluorescence intensity with a BiJ591 standard binding curve performed on both cell lines. For quantitative determination of PSMA cell surface receptors, 1 × 10^6 of each cell line/sample were stained with anti-PSMA murine J591 antibody by indirect immunofluorescence using the QIFIKIT (Aglient). PSMA-positive PCa cells (CWR22Rv1, LNCaP, and MDA PCa 2b) were incubated with each IVR sample and the BiJ591 amount was determined by comparing the fluorescence intensity with a BiJ591 standard binding curve performed on both cell lines. For quantitative determination of PSMA cell surface receptors, 1 × 10^6 of each cell line/sample were stained with anti-PSMA murine J591 antibody by indirect immunofluorescence using the QIFIKIT (Aglient). PSMA-positive PCa cells (CWR22Rv1, LNCaP, and MDA PCa 2b) were incubated with each IVR sample and the BiJ591 amount was determined by comparing the fluorescence intensity with a BiJ591 standard binding curve performed on both cell lines. For quantitative determination of PSMA cell surface receptors, 1 × 10^6 of each cell line/sample were stained with anti-PSMA murine J591 antibody by indirect immunofluorescence using the QIFIKIT (Aglient). PSMA-positive PCa cells (CWR22Rv1, LNCaP, and MDA PCa 2b) were incubated with each IVR sample and the BiJ591 amount was determined by comparing the fluorescence intensity with a BiJ591 standard binding curve performed on both cell lines.
This technology is based on a solution of biodegradable DB-PEG-PLA and TB-PEG-PLA copolymers dissolved in a biocompatible solvent, which was tripropionin (Sigma-Aldrich) in this study. To prepare the polymeric vehicle solutions, DB and TB copolymers, provided by MedinCell, were added to tripropionin in a 10 mL glass vial and placed on a roller mixer at room temperature until complete dissolution of the polymer, confirmed by visual inspection. Subsequently, spray-dried BiJ591 drug was weighed and dispersed into the polymer vehicles to yield a 6% (w/w) spray-dried cake loading. Final formulations were magnetically stirred until achieving full homogeneity. Different formulations were tested by keeping constant the copolymers:tripropionin:BiJ591 ratio and changing the composition of the DB. Copolymers used for polymeric candidates are summarized in Supplementary Table S2.

Mechanical properties of polymeric vehicles

The dynamic viscosity of vehicles was measured using an Anton Paar MCR301 rheometer. After preparation, vehicles were homogenously conditioned at 25°C using a Peltier microplate set on the rheometer. A total of 200 μL of vehicle was put at the center of the measuring plate. Thereafter, the geometry, a Cone-Plate geometry with a diameter of 25 mm and a contact angle of 2° (CP-25), was lowered, applying a gap of 0.051 mm between the geometry and the measuring plate. A decreasing rotation shear rate from 1,000 to 0.1/second was applied. For each formulation, the mean value (n = 3) of the dynamic viscosity at the highest shear rate (1,000/second) was reported in mPa.s. Injectability studies were performed using a texturometer (Lloyd Instruments) in compression mode at room temperature. Polymeric vehicles were loaded in a 0.5-mL syringe equipped with a 23 G, 1-inch needle. The injection force necessary to maintain a constant flow rate of 1 mL/minute was determined in triplicate for each vehicle.

IVR and stability of formulated BiJ591

IVRs of BiJ591 from formulation candidates were performed in a sodium phosphate buffer (pH 6.8) supplemented with 0.005% Tween 80 to avoid protein adsorption at low concentrations. A total of 50 μL of each formulation was injected into 20 mL of buffer in glass vials that were capped and placed at 37°C under continuous orbital shaking during 66 days. At given time points, the medium was collected and replaced by preheated buffer. Released protein concentration in the medium was determined by size exclusion (SEC) HPLC analysis. To improve sensitivity, protein quantification relied on the intrinsic fluorescence of the protein (excitation and emission wavelengths were 275 nm and 330 nm, respectively). Cumulative release profiles were built taking into account the total protein cargo contained in the injected formulations. Stability of BiJ591 monitored during 4 weeks in the TB1/DB4 formulation stored at 4°C or room temperature. At each time point, a small amount of formulation (in triplicate) was precisely weighed in a microtube and dissolved in ethyl acetate. After centrifugation, the protein pellet was washed twice with 500 μL ethyl acetate and dried for 1 hour in a vacuum oven. Dry pellet was solubilized in 1 mL of release buffer. After centrifugation for 10 minutes at 16,000 x g, the protein contained in the supernatant was analyzed and quantified by SEC-HPLC.

In vivo studies

Mice were purchased from Charles River Labs and all animal procedures were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medicine.

Pharmacokinetics of BiJ591 solution and formulations

Two In vivo pharmacokinetic single-dose studies were carried out in male BALB/c mice weighing 20–30 g that were randomly divided into 3 animals per treatment group. The intravenous BiJ591 solution tested in the first pharmacokinetic study at 1 mg/kg allowed to select the dose level to be used in the second study. Subsequently, mice were administered (using a 25G needle) at 15 mg/kg dose level with either subcutaneous BiJ591 formulation TB1/DB1 or TB1/DB4 (selected on the basis of the IVR data), or subcutaneous (interscapular area), or intravenous BiJ591 solution. The volume injected was 50 μL (ca. 2.5 mL/kg) of formulation or PBS pH 7.4 solution. Blood samples (100 μL) were collected from BiJ591-treated animals only at the following time points (3 animals per time point): 0 (predose), 1, 3, and 7 hours, and then 1, 2, 4, 7, 9, 11, 14, 16, and 21 days after administration.

BiJ591 plasma concentrations were determined by the following ELISA assay: Anti-PSMA 7E11 (40 μg/mL), binding a cytosolic epitope of PSMA, was coated to High Bind Microplates (Costar) plate and incubated overnight at 37°C. LNCaP membrane preparation was then added to each well. After 2-hour incubation at room temperature and 3 wash cycles with PBS-Tween (0.05%). BiJ591 standards, controls, and mouse plasma samples were added and incubated for 4 hours at room temperature. After another PBS-T wash step, BiJ591 was targeted adding a rabbit anti-6His epitope tag antibody (1:1500, Genscript) for 1 hour at room temperature. The plates were then washed with PBS-T and an alkaline phosphatase–conjugated anti-rabbit IgG secondary antibody diluted 1:5,000 was added and incubated in each well for 1 hour at room temperature. The plates were then washed with PBS-T and an alkaline phosphatase–conjugated anti-rabbit IgG secondary antibody diluted 1:5,000 was added and incubated in each well for 1 hour at room temperature. After a last PBS-T wash, 100 μL of PNPP substrate (Thermo Fisher Scientific) was added to each well. After 30 minutes, the optical density was measured at 405 nm using a plate reader. BiJ591 concentration in each plasma sample was determined according to the standard optical density measured at the same time.

Individual pharmacokinetic parameters such as C0 (intravenous), Cmax, and t1/2 (area under the curve (AUC)), and half-life (t1/2) were then calculated using the validated software Phoenix 64 WinNonlin Version 7.0 (Pharsight Corporation). The plasma concentration–time data obtained for each formulation were analyzed using a noncompartmental analysis (NCA) for both routes (intravenous and subcutaneous). The absolute subcutaneous bioavailability was estimated on the basis of the intravenous and subcutaneous AUCs extrapolated to infinity.

Paraffin embedding and histologic assays

The polymeric depots, tissues, and tumors of all mice were formalin fixed, embedded in paraffin blocks, and sectioned (5 μm). For immunogenicity assays, sections were stained with hematoxylin and eosin (H&E) and provided to a pathologist who examined the degree of inflammation of the tissue surrounding the polymeric depot. To observe T-cell infiltration, tumor and injection site skin sections were processed for immunostaining using anti-human CD3 antibody (Dako) and appropriate
peroxidase-conjugated secondary antibody (Jackson Immuno-
Research). Histologic images were taken by using a CX41 micro-
scope and an OMAX A3550I digital camera (Olympus).

Hematologic assays
A group of 15 BALB/c mice was administered subcutaneous with 50 μL of the vehicle of TB1/DB4 formulation, that is, a polymeric solution with similar copolymers concentration to that of the formulation, without BiJ591. Another control group of 15 BALB/c mice was injected subcutaneous a similar volume of PBS. The amount of circulating white blood cell (WBC), neutrophil (NEU), monocyte (MON), lymphocyte (LYM), red blood cell (RBC), hemoglobin (HGB), platelet (PLT), and the mean platelet volume (MPV) were recorded after each blood withdrawal (50–100 μL at days 1, 7, 14, 21, and 28) using a complete blood count (CBC) instrument.

BiJ591 formulation antitumor activity
LNCaP (10 × 10⁶), CWR22Rv1, PC-3 WT, or PC-3 PSMA cells (5 × 10⁵) were injected subcutaneously (flank area) with Matrigel (Corning) in 6–8-week-old male SCID mice. When tumors reached a minimum volume of 150–200 mm³, tumor-bearing mice were randomized in different treatment groups (n = 8 per group) and were treated with a single intravenous injection of huPBMCs (5 × 10⁶). Two hours later, mice were administered either a single subcutaneous injection (interscapular area) of BiJ591 TB1/DB4 formulation (15 mg/kg in 50 μL), or a single subcutaneous injection of BiJ591 solution (15 mg/kg in 50 μL), or a daily intravenous injection of BiJ591 solution (1 mg/kg in 200 μL daily for 15 days), or a daily intravenous injection of BiJ591 solution (15 mg/kg in 50 μL) or a daily intravenous injection of BiJ591 solution (1 mg/kg in 200 μL daily for 15 days), or a daily intravenous injection of BiJ591 solution (15 mg/kg in 50 μL). The control mice groups were administered either 50 μL s.c. TB1/DB4 polymeric vehicle (interscapular region) or a daily intravenous injection of PBS (200 μL per day during 15 days). Tumors were measured using a caliper and volume was calculated using the formula V = (tumor length × tumor width × tumor depth)/2. Concerning the PC-3 WT/PC-3 PSMA xenografts growth study, explanted tumors were photographed and weighed at the end of the experiment.

Statistical analysis
The level of significant difference in tumor volume progression was determined by the two-way ANOVA. All statistical analyses were performed using Prism Version 5 (GraphPad Software). A P value of less than or equal to 0.05 was considered significant in all analyses herein. Descriptive statistics of the pharmacokinetic parameters were performed.

Results
Purification and characterization of the recombinant PSMA/CD3 BiJ591
After large-scale purification in CHO cells and purification, analysis by SDS-PAGE gel showed a 55-kDa protein corresponding to the expected size of the bispecific antibody (Fig. 1B) with a similar purity (95%–98%) and yield than the scFv of J591 antibody (10 mg per liter of CHO supernatant). By flow cytometry, BiJ591 binding to PSMA and CD3 was compared with the two parental mAbs used to design this bispecific antibody, HuJ591, which is a deimmunized version of anti-PSMA J591 antibody (20, 22), and OKT-3, a murine mAb targeting CD3 (23). BiJ591 was shown to bind to PSMA-positive LNCaP PCa cells and CD3-positive Jurkat T cells, keeping the binding properties of the parental mAbs with an apparent lower affinity to CD3, which could be explained by the proximity of the 6×His-Tag used to detect the BiJ591 and binding site to CD3 (Fig. 1C). SEC-HPLC analysis of the purified BiJ591 showed a major peak and two larger species of the bispecific, probably dimer and trimer or multimer (Supplementary Fig. S1A). Each peak was purified and showed similar binding properties to PSMA and CD3 (Supplementary Fig. S1B and S1C). Finally, no binding signal was detected with PSMA/CD3-negative PC-3 WT PCa cells (Supplementary Fig. S2A).

BiJ591 mediates T-cell activation and cytotoxicity of PSMA-positive PCa cell lines
The potency of BiJ591 to induce T-cell cytokine release in the presence or absence of PSMA-positive LNCaP cells after 24 hours of incubation was first assessed by flow cytometry. A BiJ591 dose-dependent increase of the 6 different cytokines was observed only when LNCaP and T cells were co-incubated with the bispecific antibody (Fig. 2A). In the absence of LNCaP cells, there was no substantial variation in the cytokine release profile of T cells. Upon BiJ591 incubation, IL2, an interleukin that promotes the proliferation and differentiation of T cells into effector and memory T cells (24), was the most increased cytokine in these experiments (~240-fold).

Next, we compared the capacity of BiJ591, humanized J591 (huJ591) and the scFv J591, as a negative control, with redirect purified human PBMCs and T-cell lysis against PSMA-negative (PC-3 WT), PSMA-low (CWR22Rv1) and PSMA-high (LNCaP, MDA PCA 2b) prostate cancer cell lines (Supplementary Fig. S2A and S2B). Although no lysis was observed when the three J591 constructs were co-incubated with PC-3 WT and huPBMCs/ T cells, we showed that BiJ591-mediated killing was higher than the antibody-dependent cell cytotoxicity induced by huJ591 on PSMA-positive PCa cells and its EC50 was positively correlated with the surface expression of PSMA in these cell lines (Fig. 2B). Moreover, BiJ591 was the only construct able to induce PSMA-positive PCa cells lysis by purified T cells (Fig. 2C). Finally, the cytotoxic efficiency of BiJ591 was analyzed and compared with the molar equivalent concentration of huJ591 at different E:T ratios in LNCaP cells. As shown in Fig. 2D, BiJ591 provides more efficient huPBMCs and T-cell cytotoxicity than huJ591. Thus, these results demonstrate that BiJ591 is able to induce a PSMA-specific T-cell-dependent activation and T-cell–mediated killing of PCa cells.

BiJ591 displays short half-life and strong antitumor activity in mouse models
To determine how frequently BiJ591 should be administered for tumor therapy in vivo, the preliminary pharmacokinetic analysis of the bispecific antibody was performed in BALB/c mice. After intravenous injection of 1 mg/kg BiJ591, the plasma BiJ591 concentration was measured by ELISA, demonstrating a half-life of approximatively 9 hours (Fig. 3A). On the basis of BiJ591 concentration was measured by ELISA, demonstrating a short half-life and strong antitumor activity in mouse models.

Leconet et al.

Published OnlineFirst June 11, 2018; DOI: 10.1158/1535-7163.MCT-17-1138

Mol Cancer Ther; 17(9) September 2018 Molecular Cancer Therapeutics

Downloaded from mct.aacrjournals.org on November 13, 2018. © 2018 American Association for Cancer Research.
BiJ591 dose) animals. A significant growth inhibition of the BiJ591 group was observed compared with saline and huJ591-treated animals (P < 0.0001 for both). Specifically, the mean tumor volume in BiJ591-treated mice was reduced by 57% at day 33 compared with 16% for the huJ591-treated mice (Fig. 3B). Moreover, the T-cell infiltration into the tumor during the treatment in BiJ591 and control groups was analyzed by IHC. Whereas T cells were detected in the tumor stroma of control group tumors up to 1 week, a daily treatment with BiJ591 resulted in T cells within the stroma for 2 weeks as well as infiltrating the center of the tumor (Fig. 3C).

Characterization of spray-dried BiJ591

To preserve the functionality and integrity of the bispecific antibody within the polymeric formulation, choice was made to maintain it in its solid-state form throughout the formulation process. After spray drying the protein, a monodispersed particle size distribution was obtained (Fig. 4A). Particle size was measured by laser diffraction and mean volume diameter was determined to be 9.66 μm. Final water content in the as-obtained powder was determined as 3.1% (w/w). Particle size values d10, d50, and d90 were, respectively, 2.88, 7.31, and 19.71 μm. The protein content in the spray-dried cake was confirmed to be 10% (w/w). Then, using flow cytometry, BiJ591 was shown to preserve its binding properties to PSMA and CD3 before and after spray drying. (Fig. 4B).

Polymeric formulations preserve BiJ591 stability and control its release in vitro

The rheological and injectability behavior of the BiJ591 polymeric vehicles are shown in Fig. 4C. These formulations differ only by the PLA:PEG ratio of the DB (Supplementary Table S2), whose value is correlated to the hydrophobicity of the formulation, and show an increase of both viscosity and injectability directly related to this ratio. The obtained values of viscosity and injectability of these vehicles are within the acceptable specifications determined by the provider for the production scalability and a clinical utilization, reinforcing the potential of these drug products. Once the physicochemical characteristics of the selected vehicles were demonstrated to be acceptable, these vehicles were used to formulate BiJ591. Figure 4D shows the in vitro dissolution profile of the bispecific antibody from each of these formulations. The release profile of BiJ591 from TB1/DB1 shows a fast-initial release phase of 50% of the bispecific antibody during the two first weeks and a slower second phase. Concerning the three other formulations,
a lower initial burst and a lag phase were observed before a subsequent slower release step. Surprisingly, the relationship between the release profile and the enhancement of the vehicle hydrophobicity and viscosity was not clear. It was expected that formulations containing hydrophilic copolymers would yield more porous depots where the diffusion of the bispecific...
antibody to the aqueous medium would be enhanced. Indeed, the fastest release was observed with the less hydrophobic formulation TB1/DB1. However, there were no substantial differences among the three other formulations despite the different hydrophobicity of the polymers within the formulation. In parallel to the IVR, the amount of released BiJ591, from TB1/DB1 and TB1/DB4, able to bind PSMA and CD3 was also measured. The release profile of functional BiJ591 obtained from these flow cytometry studies on LNCaP and Jurkat cells was similar to the SEC-HPLC profile demonstrating that the bispecific antibody integrity was preserved within the depots throughout the IVR duration (Fig. 4E). Moreover, stability of BiJ591 in the TB1/DB4 formulation was investigated at 4°C and room temperature storage conditions (Fig. 4F). A protein recovery between 94% and 99% at both temperatures during the first 3 weeks was observed while a slow decrease (92%) at day 28 could be noted. Altogether, these results confirm that the polymer-based technology can control the delivery of the protein, although preserving its functionality in the formulation as well as in the solid depot. Regarding these results, the ability of the formulations with the most disparate viscosity/hydrophobicity properties (TB1/DB1 and TB1/DB4) to control the release of the bispecific antibody was evaluated in vivo.

Polymeric formulations improve substantially BiJ591 stability and pharmacokinetic parameters

Following the results obtained during the first in vivo antitumor assay, a 15 mg/kg dose level of BiJ591 has been selected to be equivalent to a 2 weeks daily treatment at 1 mg/kg. The semilogarithmic plot of the mean plasma concentration–time curves of BiJ591 formulation candidates TB1/DB1 and TB1/DB4 after subcutaneous dose was compared with those of unformulated BiJ591 after intravenous and subcutaneous dose as shown in Fig. 5A. The plasma concentrations and the main pharmacokinetic parameters are reported in Supplementary Tables S3 and S4, respectively. The expected pharmacokinetic outcomes were reached as these candidates positively modified the pharmacokinetic profile of the protein; the maximum plasma levels (Cmax) were, respectively, 11- and 1.5-fold lower than the bolus intravenous and subcutaneous injections, whereas the half-life of the bispecific antibody was improved from 16 hours to up to 4 days and 8 days for TB1/DB1 and TB1/DB4, respectively. In addition, the AUC and the bioavailability of the protein released from the formulation candidates was increased up to 1.9-fold compared with the subcutaneous bolus of BiJ591 solution (same injection site for the three subcutaneous formulations). Moreover, both candidates provided a sustained release of the protein over time, with plasma concentrations still quantifiable after 21 days postadministration. However, the most hydrophobic and viscous formulation, TB1/DB4 candidate, provided the highest sustained plasma levels from day 9 onwards. Encouragingly, these results correlate with the delivery profiles obtained in vitro as the release from TB1/DB4 formulation was the slowest one in both experiments. On the basis of this long-term release in vivo, the TB1/DB4 formulation candidate was selected for the following studies.

TB1/DB4 polymeric vehicle showed no blood toxicity and low inflammation in vivo

Possible hematologic toxicity and inflammation of the TB1/DB4 vehicle were evaluated over a month after subcutaneous injection in BALB/c mice by complete blood count (CBC) and IHC of the injection site. As shown in Fig. 5B and
Supplementary Table S5, white blood cells counts were equivalent to those obtained after subcutaneous administration of PBS, with some variations in the monocyte population (MON) but not exceeding 1.6-fold (day 21). Animal health parameters such as red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT) were in the same range as the control (Fig. 5B). Although some hematologic parameters appeared lower than the standard BALB/C range, they were similar to the PBS control group at each time point and might be due to the sensitivity of the instrument (Supplementary Table S5). Histologic analysis revealed slight inflammation characterized by an acute reaction occurring during the first week with infiltration of polymorphonuclear leukocytes (PMN), mostly basophils, around the depot (Fig. 5C). The depot gradually degraded, becoming smaller and multilocular, and the inflammation evolved into subacute histology, with less granular basophil cells, and then chronic (presence of fibroblasts and fibrosis). No antigen-related inflammation (no multinuclear macrophages) was detected.

BiJ591 TB1/DB4 formulation improves T-cell infiltration and antitumor activity in vivo
Because a correlation between BiJ591 therapeutic effect and CD3 T-cell infiltration was observed (Fig. 3C), we sought to

Figure 4. In vitro characterization, functionality, and release of BiJ591 formulated in polymeric vehicles. A, Particle size distribution of spray-dried BiJ591 determined by laser diffraction. B, Binding of various concentrations (0.001–100 μg/mL) of BiJ591 before and after spray drying to PSMA and CD3 receptors by flow cytometry. C, Effect of the molecular ratio of PLA units over PEG units in polymeric vehicles DB on their viscosity and injectability. D, Impact of the PLA:PEG DB ratio on BiJ591 in vitro release from polymeric formulations. All formulations contained 6% of sprayed BiJ591. The protein was dosed by SEC-HPLC. E, Analysis of the amount of BiJ591 able to bind PSMA and CD3 after IVR from TB1/DB1 and TB1/DB4 formulations by flow cytometry. Each time point PSMA or CD3 binding fluorescence intensity was compared with a standard BiJ591 curve to determine the amount of functional BiJ591 and compare it with the IVR dosing by SEC-HPLC. F, Stability of BiJ591 in TB1/DB4 formulation at 4°C and room temperature. Formulation was dissolved in ethyl acetate and BiJ591 was analyzed and quantified by SEC-HPLC.
dissect the effects of TB1/DB4 on T-cell infiltration of LNCaP tumors compared with a single subcutaneous administration of the same quantity of BiJ591 in solution (Fig. 6A). IHC characterization of T cells in LNCaP tumor xenografts of NOD-SCID mice treated with BiJ591-TB1/DB4 formulation revealed a substantial infiltration of CD3+ T-cells for at least 21 days. In contrast, administration of BiJ591 subcutaneous in solution had little effect on T-cell infiltration. Concerning the injection site, we did not observe any presence of human T cells in both bolus and polymer groups.

Then, in vivo antitumor efficacy of formulated BiJ591 was examined in high PSMA LNCaP and low PSMA CWR22Rv1 xenografts (Fig. 6B and C). Drug administration was preceded 2 hours before by intravenous administration of human PBMCs. Compared with the PBS control group, LNCaP tumor growth rate in mice treated with BiJ591-polymeric formulation depot was slower and tumor volume was significantly smaller than mice treated with intravenous or subcutaneous BiJ591 solution (P = 0.0215 and 0.0035, respectively). Moreover, the median delay to reach a tumor volume of 2,000 mm³ was much longer in the BiJ591 formulation group (+25 and +14 days vs. control and intravenous bolus BiJ591, respectively). Concerning CWR22Rv1 xenografts, a significant antitumor activity (P = 0.0005) of the formulated BiJ591 was observed compared with the control vehicle group and a daily injection intravenous of BiJ591. The median delay to reach a tumor volume of 2,000 mm³ was also longer (+18 and +16 days vs. control and intravenous bolus BiJ591, respectively). To ensure that the therapeutic effect was specific to PSMA expression, a third in vivo experiment was conducted, consisting in injecting PC-3 wild-type subcutaneously and PSMA-transfected cells, respectively, into the left and the right flank of each mouse followed by later treatment with either polymer vehicle, BiJ591 daily solution intravenous or BiJ591-TB1/DB4 formulation (Fig. 7A). No differences of tumor growth rate between the two cell lines in the polymer vehicle group were measured.
whereas treatment with BIJ591 intravenous or formulated bi-specific antibody translated into a significant delay of the tumor progression of PC-3 PSMA only (Fig. 7B). These results were confirmed by harvesting and weighing the tumors (Fig. 7C and D). Altogether, these in vivo results demonstrate that the BIJ591 formulation significantly reduces prostate tumor xenograft growth and is even more efficient than a daily administration of the drug for the same therapeutic dosing.
Discussion

Small antibody fragments have recently emerged as new therapeutic and medical imaging tools in cancer, particularly due to their better tissue penetrance, their capacity to be produced in prokaryotic models and their ability to preserve the binding properties of their parental antibodies (25). Nevertheless, it becomes challenging, like other small proteins, to control and maintain the circulating therapeutic plasma concentrations of these fragments as they are generally rapidly excreted through the kidney. Several strategies for half-life extension have been proposed using genetic fusion or chemical conjugation of the antibody fragment to an IgG Fc, human serum albumin, or polyethylene glycol (26). Some of these strategies have been applied to small bispecific antibody constructs (27–33) with preclinical reported success, but they all imply a modification of the original protein and a plasma exposure of a higher quantity of drug at the beginning of the administration, which could become a disadvantage regarding its potential toxicity. Concerning blinatumomab, infusion of a constant concentration of the drug using a pump enables to keep the drug level between the therapeutic and toxic range but can become challenging for the comfort and mobility of the patient. In this study, a biocompatible and biodegradable delivery method was designed to sustain the release of a BiTE, BiJ591, in prostate cancer xenograft models and potentially reduce/eliminate tumor burden.

The bispecific antibody was generated by fusing the scFv of J591, a clinical stage deimmunized mAb targeting PSMA, and the scFv of the clinically approved anti-CD3 OKT-3 antibody (20, 22, 23). Like other similar studies testing anti-PSMA/CD3 bispecific antibodies (34–36), the ability of BiJ591 to bind both PSMA and CD3, and also to induce a PSMA-specific cytotoxicity in vitro was demonstrated. In vivo, the short half-life and the therapeutic effect of this bispecific antibody on PSMA-positive PCa xenografts have been confirmed after daily intravenous injection.

The challenge when changing the method of administration from a daily intravenous treatment to a single subcutaneous long-acting injection is to preserve the stability and the functionality of the protein in the polymeric microenvironment.

Figure 7.
BiJ591-TB1/DB4 inhibits specifically PSMA-positive xenografts. A, Experimental protocol, in vivo study was performed in NOD/SCID mice xenografted at the same time with the same cell number \((5 \times 10^4)\) of PC-3 WT (left flank) and PC-3 PSMA (right flank). When tumor size reached 150–200 mm³, all groups received intravenous administration of human PBMCs. Negative control group was inoculated subcutaneous with TB1/DB4 vehicle, whereas the other groups received the indicated doses of BiJ591 in solution intravenous (2 weeks daily injection, 1 mg/kg) or formulated in TB1/DB4 subcutaneous (single injection, 15 mg/kg). B, For each group, tumor growth was measured and compared between the two PCa cell lines. C and D, At day 20 after first treatment, mice were sacrificed, and explanted tumors were photographed and weighed. ***, \(P < 0.001\); ****, \(P < 0.0001\).
Furthermore, antibody fragments tend to be unstable and to aggregate rapidly in a soluble state. To overcome this issue, the strategy was first to add stabilizing excipients like trehalose and Tween80, for protecting BiJ591 from aggregation and from elevated temperatures induced by the spray-drying process (37, 38). Indeed, spray-dried material was preferable to lyophilized material for obtaining homogeneous dispersion in the polymer vehicles, especially at high API loadings (S. Grizot; unpublished observations). Spray-drying conditions were selected to preserve BiJ591 functionality during the process. To control the delivery of the bispecific antibody, an injectable polymeric technology relying on the formation of a depot in situ was used. More specifically, the core of the technology allows formulating a drug with a combination of TB and DB PEG-PLA copolymers solubilized in a solvent. Upon contact with aqueous environment, the copolymers precipitate entrap- ping the drug within the formed depot. The release of the drug occurs when parallel processes of solvent diffusion and degra- dation of the formed polymeric depot start. The combination of TB and DB PEG-PLA copolymers allows fine tuning the hydro- philic/hydrophobic balance of the formulation, which dictates the release kinetics of the drug as well as the degradation rate of the polymeric matrix. In this particular study, copolymers were dissolved in tripropionin, a carbon C3 small-chain triglyceride similar to triacetin, which has been used in several in situ forming gel studies (39, 40), to obtain a viscous injectable solution. While few toxicity studies have been performed with the use of tripropionin (41), some preliminary subcutaneous injection assays were conducted in rats and mice confirming the solvent biocompatibility (S. Grizot; unpublished observa- tions). Tripropionin does not solubilize spray-dried protein molecules, keeping them in their solid-state within the liquid formulation and inside the depot after injection. The mechan- ical characteristics of the bispecific antibody formulations using 4 different combinations of TBs and DBs were within the acceptable ranges provided by the copolymers provider, Med- inCell, and defined on the basis of a product that is currently in clinical development. Very encouragingly, all of them were able to sustain the in vitro release of the bispecific antibody for more than 7 weeks. Moreover, the functionality of the released bispecific antibody (from the polymer system) to bind both PSMA and CD3 receptors was maintained. In vivo, the subcu- taneous polymeric formulations allowed to control and main- tain the circulating plasma concentration of BiJ591 for at least 21 days. Regarding the antitumor activity of the delivery system and comparing with a daily administration of BiJ591 for 2 weeks, a single subcutaneous injection of TB1/DB4 formulation containing an equivalent total amount of drug showed an improved growth inhibition of prostatic xenografts. This improvement was even more pronounced in low PSMA- expressing tumors like CWR22rv1, where a daily administration of the drug was unable to induce a significant therapeutic effect, whereas the controlled delivery approach did have an impact on tumor growth. This might be explained by the continuous pres- ence of the bispecific antibody in the circulation over a longer duration. Moreover, the antitumor effect was specific to the controlled release of BiJ591 and not to the presence of copolymers or solvent as PSMA-negative PC-3 xenograft tumor growth was not affected by the same formulation in the same way as PSMA- positive tumor growth was not modified by polymeric vehicles.

Control of the initial burst would be a key to extend the total duration of release and is also a prerequisite for the delivery of therapeutics activating the immune system. A small burst could be an advantage to rapidly saturate the tumor receptors and recruit the T cells, but a large burst would induce an uncontrolled activation of the immune system translating into a severe cytokine release syndrome (42). Regarding this study, the promising behavior of the BiJ591 polymeric formulations can still be improved in terms of $C_{\text{max}}$ reduction and lower $C_{\text{max}}/C_{\text{ss}}$ (steady state concentration) ratio. However, the poor in vitro/in vivo correlation (IVIVC) could hamper the optimization of the for- mulations. The difference of release profiles in vivo compared with in vitro can probably be explained by several factors: the absence in the release buffer of living cells or enzymes but also the interstitial fluid flow and tissue pressure applied on the depot. All these variables can modify the absorption of the protein as well of the solvent in the subcutaneous area, the rate of the phase inversion and the degradation kinetics of the depot. An interesting add-on to this drug delivery approach would be formulating the drug preencapsulated in particles (43–46). In fact, in the presence of certain excipients, some particles have the convenience to provide a stable microenvironment for the proteins and to be more compatible with in situ forming gels than the proteins in terms of hydrophobicity and interactions with the gel copolymers (47–49). Moreover, even if the drug loading capacity of particles are usually lower than in situ forming gels, the high specific activity of BiJ591 does not require high capacity loading (6%–12% for a 2–4-week delivery, respectively). This combination delivery sys- tem, by preserving the particles around the injection site, would also enable the possibility to treat oligo-metastases locally or maintain the bispecific antibody in the postsurgical area to prevent possible local recurrence.

In conclusion, an injectable in situ biodegradable polymer- based protein delivery system was successfully designed to pro- long the in vivo elimination half-life and the therapeutic effect of a small bispecific T-cell engager targeting PSMA in prostate cancer. The polymeric technology preserves the stability and functionality
of the protein and the composition of the polymers can modulate the release profile in vitro and in vivo. Very encouragingly, a significant decrease in tumor growth was observed in animal models upon the administration of the formulated bispecific antibody. This technology represents a promising therapeutic approach and could be transposed to other cancer types using similar bispecific antibodies scaffolds able to target different tumor markers.

Disclosure of Potential Conflicts of Interest
N.H. Bander has ownership interest (including stock, patents, etc.) in BZL Biologics, LLC. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: W. Leconet, N.H. Bander
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Leconet, C. Moltmier, M. Oster, J.S. Batra, S. Grizot, N.H. Bander
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Leconet, S.L. Lamer-Déchamps, C. Moltmier, T. Vilmin, M. Oster, A.L. Noriega, N.H. Bander
Writing, review, and/or revision of the manuscript: W. Leconet, H. Liu, M. Gao, S.L. Lamer-Déchamps, M. Oster, J.S. Batra, A.L. Noriega, S. Grizot, N.H. Bander
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Leconet, S.L. Lamer-Déchamps, S. Kim, T. Vilmin, F. Liu, V. Navarro, N.H. Bander
Study supervision: W. Leconet, H. Liu, A.L. Noriega, N.H. Bander

Acknowledgments
The authors wish to thank Dr. Loic Longeart for histopathology studies assistance. The work described in this publication has been funded with support from MedinCell SA (France) and the WCM Urologic Oncology Research Fund (both granted to N.H. Bander).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 15, 2017; revised April 5, 2018; accepted June 4, 2018; published first June 11, 2018.

References
17. Chang DP, Caprielli VK, Rea J, Kelley R, Rajagopal K. Investigation of fragment antibody stability and its release mechanism from poly(Lactide-


Molecular Cancer Therapeutics

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Wilhem Leconet, He Liu, Ming Guo, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-17-1138

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2018/06/09/1535-7163.MCT-17-1138.DC1

Cited articles
This article cites 47 articles, 8 of which you can access for free at:
http://mct.aacrjournals.org/content/17/9/1927.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/17/9/1927.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.